A documented case of BRAF V600E-mutated undifferentiated sarcoma demonstrated successful treatment with a combination of BRAF and MEK inhibitors, suggesting that the BRAF V600E mutation could be a viable therapeutic target when addressed with dual BRAF and MEK inhibition (192). This evidence concerns the gene MAP2K7 and undifferentiated (embryonal) sarcoma.